Menu
Solution
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
All Resources
Blog
Case Studies
Education
CME
News
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
Solution
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
All Resources
Blog
Case Studies
Education
CME
News
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
SCHEDULE A DEMO
Home
Resources
Exon 19 Deletion
Exon 19 Deletion
Other Topics:
ATM
(2)
BRCA
(2)
Breast Cancer
(2)
cardiovascular
(1)
CDK12
(2)
CoC
(1)
EGFR
(8)
endocrinology
(1)
Exon 19 Deletion
(4)
Gastric Cancer
(3)
gastroenterology
(1)
immunotherapy
(5)
irAE
(5)
KIT Exon 11
(2)
Lung Cancer
(10)
NSCLC
(9)
Ovarian Cancer
(3)
Prostate Cancer
(2)
rheumatology
(1)
TP53
(2)
NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
,
NSCLC
Mar 1, 2021
|
Education
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
Mar 1, 2021
|
Education
Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
,
NSCLC
Feb 1, 2021
|
Education
Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
,
NSCLC
Feb 1, 2021
|
Education